© 2019 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

Advertisement

#genotype 3

Epclusa

Epclusa Has High Cure Rate in Those With Genotype 3 of Hep C and Cirrhosis

Researchers pooled data from numerous real-world cohorts from various nations.

Zepatier Plus Sovaldi Beats Hep C in Those With Cirrhosis and Genotype 3

Genotype 3 of hepatitis C virus is typically difficult to treat.

AbbVie’s New Regimen Boasts Near-Perfect Hep C Cure Rate for Genotype 3s

The investigational glecaprevir/pibrentasvir performed very well among the historically hard-to-treat group, including those with cirrhosis.

As People With Genotype 3 of Hepatitis C Age, Fibrosis Marches On

Liver fibrosis progresses as people with genotype 3 of hepatitis C virus (HCV) get older, adding urgency to the need for treatment.

AbbVie’s Hep C Combo Works Well for Those With Genotype 3 and Cirrhosis

ABT-493 and ABT-530, with or without ribavirin, showed promise among those with genotype 3 of hepatitis C in two small trials.

High Genotype 2 and 3 Hep C Cure Rates for New AbbVie Combo

AbbVie’s investigational hepatitis C treatments ABT-493 and ABT-530 posted mostly high cure rates among people with genotypes 2 and 3.

Daklinza Approved for Genotype 3

The U.S. Food and Drug Administration has approved the combination of Bristol-Myers Squibb’s NS5A inhibitor Daklinza with Gilead Sciences’ Sov...

FDA Approved Two New Hepatitis C Drugs for Genotypes 3 and 4

The FDA approved two more drugs to treat hepatitis C: Daklinza (daclatasvir) for use with sofosbuvir to treat patients with genotype 3 Techni...

FDA OK’s BMS Daklinza (Daclatasvir) to Treat Hep C Genotype 3

The FDA has approved BMS’s Daklinza (daclatasvir) to be used with Gilead Sciences’ Sovaldi (sofosbuvir) to treat genotype 3 of hepatitis C.

Genotype 3: An Unmet Need for Some

An examination of options for hepatitis C patients with genotype 3, especially for those who failed prior treatment

Daclatasvir Plus Sovaldi Shows Promise Curing Hard-to-Treat Hep C

Daclatasvir and Sovaldi, with or without ribavirin, seem likely to lead to relatively good cure rates among people with genotype 3 of hepatiti...

Success for 8 Weeks of Grazoprevir/Elbasvir Plus Sovaldi

Eight weeks of Merck’s grazoprevir/elbasvir, plus Gilead Science’ Sovaldi cured high rates of people with genotype 1 or 3 of hepatitis C.

Sovaldi, Interferon and Ribavirin Cures Almost All Hep C Genotype 3

Twelve weeks of Sovaldi (sofosbuvir), interferon and ribavirin cured 93 percent of people with the difficult-to-treat genotype 3 of hepatitis...

Hep C Treatment Is Sometimes Cost-Effective for Genotypes 2 and 3

Treating people with genotypes 2 and 3 of hepatitis C is cost effective in some circumstances, including among those with cirrhosis and among...

BMS Resubmits FDA Application for Hepatitis C Drug Daclatasvir

BMS has resubmitted an application to the FDA for approval of daclatasvir, this time in combination with Sovaldi (sofosbuvir), to treat genoty...

Hepatitis C Genotype 3: Hard to Have, Hard to Treat

Genotype 3 is not only the most treatment-resistant, it is the most aggressive type of hepatitis C.
Advertisement